Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363402 | 1.00 | SLC6A9 (0.53) | SLC6A9OPRM1SLC6A5OPRL1TSHR | |
| SCHEMBL5740969 | 0.94 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5OPRL1TSHR | |
| SCHEMBL5740972 | 0.94 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5OPRL1TSHR | |
| SCHEMBL5741464 | 0.84 | SLC6A9 (0.43) | SLC6A9OPRM1SLC6A5OPRL1TSHR | |
| SCHEMBL5741465 | 0.84 | SLC6A9 (0.43) | SLC6A9OPRM1SLC6A5OPRL1TSHR | |
| SCHEMBL5741682 | 0.83 | SLC6A9 (0.43) | SLC6A9OPRM1SLC6A5OPRL1HTR2A | |
| SCHEMBL5741677 | 0.83 | SLC6A9 (0.43) | SLC6A9OPRM1SLC6A5OPRL1HTR2A | |
| SCHEMBL5363537 | 0.77 | TSHR (0.51) | SLC6A9SLC6A5TSHRMAPK1ESR1 | |
| SCHEMBL5363541 | 0.77 | TSHR (0.51) | SLC6A9SLC6A5TSHRMAPK1ESR1 | |
| SCHEMBL5371501 | 0.72 | TSHR (0.63) | TSHRMAPK1ESR1CAMK2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176316-B2 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-13 | — | — | US | claimed |
| EP-1594840-B1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | claimed |
| EP-1594840-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | claimed |
| WO-2004072034-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-26 | — | — | WO | claimed |
| US-20040167166-A1 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | claimed |
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| EP-1871165-B1 | METHOD OF TREATING SCHIZOPHRENIA PRODROME | UNIV YALE (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7176316-B2 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1594840-B1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| EP-1594840-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072034-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| US-20040167166-A1 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | SLC6A9 58/4885OPRM1 984/4885SLC6A5 31/4885 |
| US-20040167166-A1 | Amino-piperidine derivatives | OPRL1, GRIA1, GRIN1 | SLC6A9 414/4885OPRM1 31/4885SLC6A5 160/4885 |
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | SLC6A9 58/4885OPRM1 984/4885SLC6A5 31/4885 |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | AADAT, GFPT1, BCAT1 | SLC6A9 23/4885OPRM1 1366/4885SLC6A5 7/4885 |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GDI2, GDI1, NQO2 | SLC6A9 1796/4885OPRM1 3469/4885SLC6A5 542/4885 |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | SLC7A1, BCAT1, AADAT | SLC6A9 233/4885OPRM1 518/4885SLC6A5 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.